RU2703903C2 - Местное применение антитела к hsv - Google Patents

Местное применение антитела к hsv Download PDF

Info

Publication number
RU2703903C2
RU2703903C2 RU2017102387A RU2017102387A RU2703903C2 RU 2703903 C2 RU2703903 C2 RU 2703903C2 RU 2017102387 A RU2017102387 A RU 2017102387A RU 2017102387 A RU2017102387 A RU 2017102387A RU 2703903 C2 RU2703903 C2 RU 2703903C2
Authority
RU
Russia
Prior art keywords
hsv
antibody
cell
infection
seq
Prior art date
Application number
RU2017102387A
Other languages
English (en)
Russian (ru)
Other versions
RU2017102387A (ru
RU2017102387A3 (https=
Inventor
Михаэла АРНДТ
Йюрген КРАУСС
Дирк ЕГЕР
Original Assignee
Хайдельберг Иммунотерапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хайдельберг Иммунотерапьютикс Гмбх filed Critical Хайдельберг Иммунотерапьютикс Гмбх
Publication of RU2017102387A publication Critical patent/RU2017102387A/ru
Publication of RU2017102387A3 publication Critical patent/RU2017102387A3/ru
Application granted granted Critical
Publication of RU2703903C2 publication Critical patent/RU2703903C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017102387A 2014-06-26 2015-06-25 Местное применение антитела к hsv RU2703903C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14174174.4 2014-06-26
EP14174174 2014-06-26
PCT/EP2015/064378 WO2015197763A1 (en) 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody

Publications (3)

Publication Number Publication Date
RU2017102387A RU2017102387A (ru) 2018-07-26
RU2017102387A3 RU2017102387A3 (https=) 2018-07-26
RU2703903C2 true RU2703903C2 (ru) 2019-10-22

Family

ID=51032986

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017102387A RU2703903C2 (ru) 2014-06-26 2015-06-25 Местное применение антитела к hsv

Country Status (13)

Country Link
US (2) US11267871B2 (https=)
EP (1) EP3160997B1 (https=)
JP (1) JP6649284B2 (https=)
KR (1) KR102622280B1 (https=)
CN (2) CN106488931B (https=)
AU (1) AU2015279212B2 (https=)
CA (1) CA2950489C (https=)
ES (1) ES2843277T3 (https=)
NZ (1) NZ726168A (https=)
RU (1) RU2703903C2 (https=)
SG (1) SG11201610320RA (https=)
WO (1) WO2015197763A1 (https=)
ZA (1) ZA201607813B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
US11472867B2 (en) 2017-08-30 2022-10-18 Km Biologics Co., Ltd. Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof
US12247066B2 (en) 2018-08-28 2025-03-11 Pontificia Universídad Católica de Chile Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
WO2020041911A1 (es) * 2018-08-28 2020-03-05 Pontificia Universidad Catolica De Chile Anticuerpo monoclonal 11b2c7 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2
EP3941524A1 (en) * 2019-03-19 2022-01-26 Albert Einstein College of Medicine Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2022002802A1 (en) * 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa HSV gEgI HETERODIMER ANTIBODIES
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20260001939A1 (en) * 2022-03-02 2026-01-01 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
TW202426053A (zh) * 2022-09-02 2024-07-01 聯合生物製藥股份有限公司 單純皰疹病毒感染的治療
EP4727967A1 (en) 2023-06-16 2026-04-22 Heidelberg ImmunoTherapeutics GmbH Novel anti-hsv antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018634A1 (en) * 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
EP1222281B1 (en) * 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
US20070274997A1 (en) 2003-07-25 2007-11-29 Anthony Simmons Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
PL2248825T3 (pl) * 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
EP2694542A4 (en) * 2011-04-08 2014-10-08 Univ Duke HERPES SIMPLEX VIRUS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody

Also Published As

Publication number Publication date
RU2017102387A (ru) 2018-07-26
CN106488931B (zh) 2021-12-28
US20220169705A1 (en) 2022-06-02
EP3160997A1 (en) 2017-05-03
JP6649284B2 (ja) 2020-02-19
RU2017102387A3 (https=) 2018-07-26
WO2015197763A1 (en) 2015-12-30
EP3160997B1 (en) 2020-10-28
CN106488931A (zh) 2017-03-08
JP2017520572A (ja) 2017-07-27
KR102622280B1 (ko) 2024-01-08
ES2843277T3 (es) 2021-07-16
AU2015279212A2 (en) 2017-04-27
CA2950489C (en) 2022-09-20
NZ726168A (en) 2022-05-27
CN114306596A (zh) 2022-04-12
AU2015279212A1 (en) 2016-12-01
BR112016030422A2 (pt) 2017-10-24
CA2950489A1 (en) 2015-12-30
AU2015279212B2 (en) 2020-08-20
US11267871B2 (en) 2022-03-08
US20170152304A1 (en) 2017-06-01
SG11201610320RA (en) 2017-01-27
KR20170020423A (ko) 2017-02-22
ZA201607813B (en) 2018-05-30

Similar Documents

Publication Publication Date Title
US20220169705A1 (en) Topical application for an anti-hsv antibody
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2019528050A (ja) 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法
EP2308895A1 (en) Anti-HSV antibody
Krawczyk et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus
JP7145862B2 (ja) 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片
Li et al. Monoclonal antibody against EV71 3Dpol inhibits the polymerase activity of RdRp and virus replication
TWI402076B (zh) 抗介白素－２０抗體用於製造治療中風的醫藥組合物之用途
JP2024149479A (ja) 黄熱を処置するための方法および組成物
CN108472372B (zh) 结合不动杆菌的抗体结合剂及其用途
BR112016030422B1 (pt) Anticorpo anti-hsv e composição farmacêutica compreendendo o referido anticorpo
WO2022127739A1 (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
CN119060193B (zh) 猴痘病毒双特异抗体及其应用
EP4727967A1 (en) Novel anti-hsv antibody
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
TW202426053A (zh) 單純皰疹病毒感染的治療
TW202611068A (zh) 頭頸部異位性皮膚炎的治療
US10689435B2 (en) Therapy and prophylaxis of infectious disease caused by zika virus
WO2023131262A1 (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
WO2026067038A1 (zh) 一种用于预防或治疗破伤风的联合疫苗
KR20260026080A (ko) 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
HK40100361A (zh) 用抗il-13抗体治疗特应性皮炎的方法

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner